Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: The FINE-ONE trial.
Heerspink HJL, Birkenfeld AL, Cherney DZI, Colhoun HM, Ji L, Mathieu C, Groop PH, Pratley RE, Rosas SE, Rossing P, Skyler JS, Tuttle KR, Lawatscheck R, Scott C, Edfors R, Scheerer MF, Kolkhof P, McGill JB. Heerspink HJL, et al. Among authors: scheerer mf. Diabetes Res Clin Pract. 2023 Oct;204:110908. doi: 10.1016/j.diabres.2023.110908. Epub 2023 Oct 5. Diabetes Res Clin Pract. 2023. PMID: 37805000 Free article. Clinical Trial.
Retinal proteome alterations in a mouse model of type 2 diabetes.
Ly A, Scheerer MF, Zukunft S, Muschet C, Merl J, Adamski J, de Angelis MH, Neschen S, Hauck SM, Ueffing M. Ly A, et al. Among authors: scheerer mf. Diabetologia. 2014 Jan;57(1):192-203. doi: 10.1007/s00125-013-3070-2. Diabetologia. 2014. PMID: 24078137 Free PMC article.
Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 52-week results from a randomized controlled trial.
Mathieu C, Rudofsky G, Phillip M, Araki E, Lind M, Arya N, Thorén F, Scheerer MF, Iqbal N, Dandona P. Mathieu C, et al. Among authors: scheerer mf. Diabetes Obes Metab. 2020 Sep;22(9):1516-1526. doi: 10.1111/dom.14060. Epub 2020 May 22. Diabetes Obes Metab. 2020. PMID: 32311204 Free PMC article. Clinical Trial.
Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials.
Groop PH, Dandona P, Phillip M, Gillard P, Edelman S, Jendle J, Xu J, Scheerer MF, Thoren F, Iqbal N, Repetto E, Mathieu C. Groop PH, et al. Among authors: scheerer mf. Lancet Diabetes Endocrinol. 2020 Oct;8(10):845-854. doi: 10.1016/S2213-8587(20)30280-1. Lancet Diabetes Endocrinol. 2020. PMID: 32946821 Clinical Trial.
Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled 52-week outcomes from the DEPICT-1 and -2 studies.
Phillip M, Mathieu C, Lind M, Araki E, di Bartolo P, Bergenstal R, Heller S, Hansen L, Scheerer MF, Thoren F, Arya N, Xu J, Iqbal N, Dandona P; DEPICT-1 and DEPICT-2 Investigators. Phillip M, et al. Among authors: scheerer mf. Diabetes Obes Metab. 2021 Feb;23(2):549-560. doi: 10.1111/dom.14248. Epub 2020 Nov 24. Diabetes Obes Metab. 2021. PMID: 33145944 Free PMC article.
Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results.
Agarwal R, Anker SD, Filippatos G, Pitt B, Rossing P, Ruilope LM, Boletis J, Toto R, Umpierrez GE, Wanner C, Wada T, Scott C, Joseph A, Ogbaa I, Roberts L, Scheerer MF, Bakris GL. Agarwal R, et al. Among authors: scheerer mf. Nephrol Dial Transplant. 2022 Jun 23;37(7):1261-1269. doi: 10.1093/ndt/gfab336. Nephrol Dial Transplant. 2022. PMID: 34850173 Free PMC article. Clinical Trial.
27 results